Eli Lilly has signed a deal to co-develop and commercialize Rigel Pharmaceuticals’ R552, a novel drug with promise against a range of immunological and neurodegenerative diseases.
Rigel will receive an upfront cash payment of $125m, with the potential for up to $835m in future milestones
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?